IP Library Granted Patent US 9,234,203
Granted Patent B2
US 9,234,203 · App. 13/795,949 · Granted Jan 12, 2016

Stabilized recombinant expression plasmid vector in hafnia alvei and applications thereof

Inventors: Zhenhua Pang (Shanghai, CN); Naiqiang Li (Shanghai, CN); Charlie Liu (Shanghai, CN); Xiucai Liu (Shanghai, CN)
Assignees: Cathay Industrial Biotech Ltd.; Cathay R&D Center Co., Ltd.
C12N15/74C08G69/26C12P13/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,234,203
App. No.
13/795,949
Granted
Jan 12, 2016
Kind
B2
Abstract

One aspect of the present disclosure relates to a stabilized recombinant expression plasmid vector comprising a polynucleotide encoding an antitoxin gene which expresses a polypeptide that neutralizes a polypeptide toxic to a host cell, the toxic polypeptide being expressed by a toxin gene in the host cell, and a polynucleotide encoding a polypeptide expression product, and the stabilized recombinant expression plasmid vector is derived from a Hafnia alvei autonomously replicable backbone plasmid. Other aspects of the present disclosure relate to a transformant transformed with the stabilized recombinant expression plasmid vector disclosed herein, a method of producing biobased cadaverine using the transformant disclosed herein, and biobased cadaverine prepared by the method disclosed herein. Another aspect of the present disclosure relates to a polyamide formed using biobased cadaverine disclosed herein, and a composition thereof. Another aspect of the present disclosure relates to a method of preparing 1,5-diisocyanatopentane comprising preparing biobased cadaverine using the method disclosed herein and converting the biobased cadaverine to 1,5-diisocyanatopentane.

Claims (29)

1. A stabilized recombinant expression plasmid vector comprising:

a polynucleotide encoding a polypeptide that counteracts a toxin polypeptide toxic to a host cell, the toxin polypeptide being encoded by aat or abt gene, or mutants thereof, such that the toxin polypeptide has substantially the same function as the polypeptide encoded by aat or abt gene, in the host cell,

a polynucleotide encoding the toxin polypeptide, and

a polynucleotide encoding a polypeptide expression product, wherein:

the stabilized recombinant expression plasmid vector is derived from a Hafnia alvei autonomously replicable backbone plasmid, and the host cell is Hafnia alvei , and

the toxin gene and the antitoxin gene comprise a gene pair selected from the group consisting of aat/aai gene pair, abt/abi gene pair, and encoding functional fragments thereof.

2. The recombinant expression plasmid vector of claim 1 , wherein the toxin gene comprises a DNA sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and fragments thereof.

3. The recombinant expression plasmid vector of claim 1 , wherein the antitoxin gene comprises a DNA sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and fragments thereof.

4. The recombinant expression plasmid vector of claim 1 , wherein the backbone plasmid is selected from the group consisting of pUC, pUC18/19, pBR322, pACYC and any derived plasmids thereof.

5. The recombinant expression plasmid vector of claim 1 , wherein the polypeptide expression product is an enzyme selected from the group consisting of decarboxylase, hydrolases and phosphorylase.

6. The recombinant expression plasmid vector of claim 5 , wherein the decarboxylase is an amino acid decarboxylase selected from the group consisting of lysine decarboxylase, tyrosine decarboxylase, arginine decarboxylase, ornithine decarboxylase, and glutamate decarboxylase.

7. The recombinant expression plasmid vector of claim 6 , wherein the polynucleotide encoding lysine decarboxylase comprises a polynucleotide selected from the group consisting of haldc gene, cadA gene, and fragments thereof.

8. The recombinant vector of claim 7 , wherein the recombinant vector comprises a DNA sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, and fragments thereof.

9. The recombinant expression plasmid vector of claim 1 , wherein the toxin gene comprises a DNA sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and fragments thereof.

10. The recombinant expression plasmid vector of claim 1 , wherein the antitoxin gene comprises a DNA sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and fragments thereof.

11. The recombinant expression plasmid vector of claim 1 , wherein the backbone plasmid is selected from the group consisting of pUC., pUC18/19, pBR322, pACYC and any derived plasmids thereof.

12. The recombinant expression plasmid vector of claim 1 , wherein the polypeptide expression product is an enzyme selected from the group consisting of decarboxylase, hydrolases and phosphorylase.

13. The recombinant expression plasmid vector of claim 12 , wherein the decarboxylase is an amino acid decarboxylase selected from the group consisting of lysine decarboxylase, tyrosine decarboxylase, arginine decarboxylase, ornithine decarboxylase, and glutamate decarboxylase.

14. The recombinant expression plasmid vector of claim 13 , wherein the polynucleotide encoding lysine decarboxylase comprises a polynucleotide selected from the group consisting of haldc gene, cadA gene, and fragments thereof.

15. The recombinant vector of claim 14 , wherein the recombinant vector comprises a DNA sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, and fragments thereof.

16. A transformant obtained by transforming a recombinant expression plasmid vector of claim 1 into a host cell, wherein the host cell is a Hafnia alvei strain free of endogenous plasmids.

17. The transformant of claim 16 , wherein the Hafnia alvei strain is an industrial Hafnia alvei strain.

18. A method of producing cadaverine (1,5-pentanediamine) comprising:

1a) cultivating the transformant of one of claim 11 ;

1b) producing cadaverine using the culture obtained from step 1a to decarboxylate lysine; and

1c) extracting and purifying cadaverine from the reaction obtained from step 1b.

19. A method of preparing 1,5-diisocyanatopentane comprising:

2a) preparing biobased cadaverine according to the method of claims 18 ; and

2b) converting biobased cadaverine obtained from step 2a to 1,5-diisocyanatopentane.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2020
From: CATHAY R&D CENTER CO., LTD
To: CATHAY BIOTECH INC.
Reel/Frame 054261/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2019
From: CATHAY R&D CENTER CO., LTD.
To: CATHAY BIOTECH INC.
Reel/Frame 050328/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2019
From: CATHAY INDUSTRIAL BIOTECH LTD.
To: CIBT AMERICA INC.
Reel/Frame 048450/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: PANG, ZHENHUA; LI, NAIQIANG; LIU, CHARLIE
To: CATHAY R&D CENTER CO., LTD.; CATHAY INDUSTRIAL BIOTECH LTD.
Reel/Frame 030772/0018 →
Continuity (2)
Provisional Application 61649719 · May 21, 2012
Related Publication 20130309733A1 · Nov 21, 2013